QN523?

Research use only, not for human use.

QN523 represents a novel scaffold with drug-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines.

QN523 is a novel scaffold with agent-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines. QN523 induces apoptosis and autophagy. QN523 can be used in research of cancer.

QN523 (72 h) has cytotoxicity with IC50 values ranging from 0.1 to 5.7 μM across 12 cell lines.QN523 (0.1 and 0.5 μM; 24 and 48 h; MIA PaCa-2 cells) arrests cell cycle at S phase and delays for pancreatic cancer cells to enter the G2-M phase. QN523 induces apoptosis and autophagy of MIA PaCa-2 Cells.Cell Cycle Analysis Cell Line:MIA PaCa-2 cells Concentration:0.1 and 0.5 μM Incubation Time:24 and 48 hours Result:Delayed for pancreatic cancer cells to enter the G2-M phase because of accumulation of cells in the S phase.Apoptosis Analysis Cell Line:MIA PaCa-2 cells Concentration:0.1 and 0.5 μM Incubation Time:24 and 48 hours Result: Increased the number of apoptotic cell in time- and dose-dependent manner.

QN523 (10 and 20 mg/kg; i.p.; daily, for 44 d) inhibits tumor growth in mice of pancreatic cancer xenografts.Animal Model:NOD/SCID mice of pancreatic cancer xenografts (6 weeks of age)Dosage:10 and 20 mg/kg Administration:Intraperitoneal administration; 1-9 days (10 mg/kg), 10-44 days (20 mg/kg) Result:Delayed growth of the tumors, and no systemic toxicity.

——

Autophagy

Autophagy

Autophagy

——

——

878581-60-3

250.26

C14H10N4O

>98% (HPLC)

In Vitro:?DMSO : ≥ 16.67 mg/mL (66.61 mM)

O=C(Nc1cccc2cccnc12)c1cnccn1

——

(-20℃)

With Ice Pack

≥ 2 years